Never miss a story

Get subscribed to our newsletter


×
There are similar stockpiles for vaccines against yellow fever, meningitis and cholera. Pixabay

The vaccine alliance GAVI announced Thursday it would invest $178 million to create a global stockpile of about 500,000 Ebola vaccines, a decision that health officials say could help prevent future outbreaks from spiraling out of control.

The public-private partnership includes the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation and the World Bank, among others. The funding announcement was made after a meeting of GAVI’s board. GAVI said the investment, which it called an estimate, will be provided between now and 2025.


Since the current outbreak in eastern Congo was identified last August, health officials have immunized more than 255,000 people with a recently licensed vaccine made by Merck. To date there have been nearly 3,200 confirmed Ebola cases, including more than 2,200 deaths, in what has become the second deadliest Ebola outbreak in history.

Dr. Ngozi Okonjo-Iweala, chair of Gavi’s board, called the creation of the Ebola vaccine stockpile a “historic milestone in humanity’s fight against this horrific disease.” GAVI said “a coordinating mechanism” to decide how and when vaccines will be used will be established with partner organizations.

There are similar stockpiles for vaccines against yellow fever, meningitis and cholera. Those limited shots are doled out to developing countries by WHO, UNICEF, the Red Cross and Doctors Without Borders after receiving technical advice from others.


A healthcare worker from the World Health Organization prepares vaccines to give to front line aid workers, in Mbandaka, Congo. VOA

The Ebola vaccine stockpile will be available to all countries, but only developing countries will be able to get vaccines for free in addition to support for the logistical costs of mounting vaccination campaigns.

Jason Nickerson, a humanitarian affairs adviser at Doctors Without Borders, said the new stockpile would change how officials respond to future Ebola outbreaks.

“Knowing how many doses of the vaccine exist in the world, and then being able to get a supply of them to high-risk countries in a very quick way, gives us another tool to respond to these outbreaks,” he said.

Earlier this year, the medical charity publicly called for an independent committee to oversee Ebola vaccination efforts in Congo, saying WHO sometimes used arbitrary criteria to determine who would get immunized. It said the fact that Ebola was continuing to spread despite the large number of people vaccinated was a damning assessment of the response.

Containing this outbreak has been complicated by violence and misunderstandings in a part of Congo that had never reported an Ebola case before.

Also Read-Measles Kills 140,000 people, WHO Calls it “Collective Failure”

Last week, response activities were suspended after attacks killed four Ebola responders, including a member of a vaccination team. Multiple rebel groups operate in eastern Congo and the region has been described as a war zone.

WHO has warned continued attacks on health workers and Ebola clinics could undermine attempts to curb Ebola and prompt a resurgence of the disease. (VOA)


Popular

Unsplash

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable.

A chewing gum laced with a plant-grown protein serves as a "trap" for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, finds a new study.

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable, indicates the study published in the journal Molecular Therapy.

Follow NewsGram on Instagram to keep yourself updated.

"SARS-CoV-2 replicates in the salivary glands, and we know that when someone d sneezes, coughs, or speaks some of that virus can be expelled and reach others," said researcher Henry Daniell from the University of Pennsylvania in the US.

"This gum offers an opportunity to neutralise the virus in the saliva, giving us a simple way to possibly cut down on a source of disease transmission," Daniell added.

To test the chewing gum, the team grew angiotensin-converting enzyme 2 (ACE2) in plants, paired with another compound that enables the protein to cross mucosal barriers and facilitates binding, and incorporated the resulting plant material into cinnamon-flavoured gum tablets.

Keep Reading Show less

HUH Token

After the release of HUH Token’s White Paper and the buzz around the soon-to-be launching cryptocurrency, it’s no wonder that the crypto world is wondering whether or not Shiba Inu’s year of meme coin supremacy is coming to an end.

Shiba Inu rose to crypto fame in the august of 2020 and just a little over a year from that point, where Shiba Inu knocked Dogecoin off top dog spot… it appears that HUH Token could be set to take the cryptocurrency world by storm on its launch: Monday December 6th. And with it the possible end of Shiba Inu’s reign as the supreme meme coin.

Keep Reading Show less

HUH Token

Investing in the cryptocurrency business is one of the most intelligent choices one can make in the modern-day. In 2021, the sector exhibited its promise, with cryptocurrencies like Ethereum (ETH), Bitcoin (BTC) and Shiba Inu (SHIB) seeing optimistic growth and creating numerous billionaire investors. The market is still in its infancy, and there is an impossible number of exciting cryptocurrencies available for investment. HUH Token, for instance, is one of these, and it is releasing today!

Comprehending a cryptocurrency’s most recent release helps to compare it to previous accomplishments. HUH Token (HUH), Cardano (ADA) and Solana (SOL) are three cryptocurrencies that every crypto trader should be familiar with. These are coins with high usefulness and a robust growth plan. Cardano and Solana are two growing blockchain technologies in the crypto world.

Keep reading... Show less